BELLEROPHON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 27th, 2017 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (“Agreement”) is made as of September 26, 2017 (the “Effective Date”), by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 27th, 2017 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 26, 2017, by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
WARRANT TO PURCHASE SHARES OF COMMON STOCK OFBellerophon Therapeutics, Inc. • September 27th, 2017 • Pharmaceutical preparations • New York
This Warrant is issued to [ ], or its registered assigns (including any successors or assigns, the “Purchaser”), pursuant to that certain Securities Purchase Agreement, dated as of September 26, 2017, among Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), the Purchaser and certain other purchasers thereunder (the “Purchase Agreement”) and is subject to the terms and conditions of the Purchase Agreement.
